retatrutide heart rate Dosing Guide: 1-12 mg Weekly Triple Agonist (2026) Retatrutide Heart Data: What Surprised

Most common side effects (Phase 2 data) Approximate rates from Phase 2 trial (Jastreboff 2023)

doi: 10.1007/s10840-021-00992-2

Its not recommended for pregnant or breastfeeding women, individuals with active cancer or uncontrolled diabetes, those with untreated thyroid disorders, significant liver or kidney dysfunction, or children and adolescents

Common early complaints can include: Nausea or a mildly unsettled stomach Feeling full after smaller meals Reduced interest in food Bloating or belching Indigestion or heartburn Diarrhea Constipation Abdominal discomfort Fatigue These symptoms overlap with adverse reactions listed in current prescribing information for Wegovy and Zepbound

These findings emphasize the need to account for age and sex differences in experimental designs, and they highlight the limitations of the Bbs5 -knockout model in fully replicating the visual phenotypes observed in human BBS